The Medical AI Podcast

One of the landmarks in AI was the work on neural networks in the 1970s by Geoffrey Hinton, the "Godfather of AI". This work took place at the University of Edinburgh. This laid much of the groundwork for the plethora of modern AI-based applications so academia and the corporate sector are two very different but essential types of crucible for AI research what is a relationship between them? Is it a loving partnership? Or is it more like a Hollywood marriage with crockery regularly being thrown against the wall? With to explore this important but under-discussed area is Prof Shai Shen-Orr, Associate Prof. at Technion, the Israel Institute of Technology.

Dr. Cory Goldberg, a plastic and craniofacial surgeon and longevity researcher, dives into the exciting intersection of AI and aging science. He discusses how telomeres and epigenetic changes shape aging and debates whether aging is a disease. Dr. Goldberg emphasizes the importance of diet, exercise, and social connections for longevity. He highlights the transformative role of AI in discovering biomarkers and developing drugs, including insights into promising treatments like rapamycin. Join in as he explores the future of longevity research and the implications of technology in our quest for a longer, healthier life.

Episode 45: AI doctors: how close are they? With Robert Sargsyan, CEO of Docus. Will AI doctors eventually replace human doctors? Are they already doing so? On one hand, people like the human touch of human doctors. On the other hand, human doctors get tired, are limited in terms of the amount of data they can handle and tend to be overstretched. So where are we with the development of AI doctors? Joining me is someone at the cutting edge of this fascinating topic, Robert Sargsyan, CEO of Docus.

Irregular heart rhythms can indicate several potentially fatal health problems, including risk for heart attack and stroke. Here we discuss how AI approaches are helping to transform cardiology, with respect to detection of irregular heart rhythms. With Felix is Stuart Long, CEO of infobionic.ai

Waiting for emergency treatment, when you might already be in shock, can be a very distressing and lonely experience. A big part of the problem might be that you are feeling in the dark about what’s happening and how long you’ll be there. An already stressful situation could feel like an eternity. How can AI systems help here? Two men who have commercialised just such a thing are Aaron Patzer and Dr Justin Schrager, founders of the company Vital.

Some have suggested that the medical profession is a force of resistance in AI adoption, that it is prioritizing the protection of jobs, potentially at the cost of patients Is there any truth in that? Or is the medical profession actually protecting patients by resisting an overhasty rush to AI adoption? With me is someone who is perfectly placed to discuss this, Dr Jethro Hubbard. He is a GP. And he was also instrumental in the introduction of the BMA policy on healthcare AI integration.

AI has the potential to revolutionize clinical trials in many ways. It could make the development of new treatments faster, safer, cheaper and more personalised. One company in this space is Owkin, a unicorn startup based in Paris. With me is Dr Félix Balazard, Director of Optimized Development Solutions.

Dr. Harsha Rajasimha, CEO of Jeeva Clinical Trials, specializes in leveraging AI for clinical research efficiency. He discusses how AI can reduce costs and improve success rates in clinical trials, a process often complicated by high failure rates. Rajasimha emphasizes the need for diversity in trials to ensure inclusive healthcare solutions. He shares insights from his journey in creating tech to streamline trials, particularly for rare diseases and cancers. The conversation highlights the balance between AI innovations and the necessity of human oversight.

Counterfeit medications and medical equipment is a huge global fraud. And it is deadly - counterfeit medications can contain incorrect ingredients and even harmful components. So how far is it possible to detect this kind of fraud and how is AI a part of that effort? With me to discuss this is Roei ROY Ganzarski, CEO of Alitheon. The Medical AI Podcast is one of Feedspot's top rated podcasts: https://blog.feedspot.com/uk_ai_podcasts/

Imagine having crippling back pain, but there’s a four month waiting list for a physiotherpist. Alternatively, you have instant access to an AI-based physiotherapy system. 80% of adults have significant back pain at some point, so there’s an excellent chance that this kind of choice is one you will have to make. But can it be made to work? Is the technology ready? Would it be accepted by governments and patients? Are there issues with patient safety? With me is Finn Stevenson, who is working on precisely this idea. He is a former medic, and CEO of Flok Health.